March/April 2016

Pilot Pharmacoeconomic Analysis of Serum-derived Bovine Immunoglobulin Use in IBD

April 20, 2016

Web Exclusives

This pilot study analyzes the cost savings of utilizing a prescription medical food, serum-derived bovine immunoglobulin/protein isolate, for the management of inflammatory bowel disease in a small cohort.

Persistence With Mirabegron Versus Tolterodine in Patients With Overactive Bladder

April 19, 2016

Web Exclusives

In a retrospective analysis of the Optum database, overactive bladder patients treated with mirabegron bladder patients persisted longer with treatment than patients treated with tolterodine, and had reduced resource utilization and costs.

Antimicrobial Stewardship at the Tipping Point

April 18, 2016

Specialty Healthcare Benefits Council

Antimicrobial stewardship programs have been around for some time. However, a tipping point has yet to be achieved where most hospitals and long-term care facilities have effective programs.

Real-World Immunoglobulin Dose Adjustments and Impact on Utilization and Costs

April 18, 2016

Original Research

Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.